GW pushes ahead with £25m Nasdaq deal
AIM-listed GW Pharmaceuticals, a £72m market capitalisation British firm that makes drugs from cannabinoids, has set terms on its £25m Nasdaq capital raise, as it hopes to increase its value through a US listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts